This retrospective study included 903 patients using isotretinoin for acne (62.9% women), with a mean age of 28.6 years. Patients were started on twice-daily isotretinoin 10 to 20 mg and increased to a maximum dose of 40 to 80 mg twice daily for a duration of 4 to 9 months. There was no clinically significant anemia, thrombocytopenia, or leukopenia observed. Elevations in triglycerides, ALT, and AST resolved at follow-up upon completion of isotretinoin treatment. Risk factors for increased triglyceride levels included obesity (BMI >30), increased baseline triglyceride levels, and concomitant medications. Increases in both ALT and AST occurred in 7 patients, which were all attributed to concomitant alcohol use.
Given that transient alterations of lipid and liver aminotransferases levels tend to be clinically insignificant, and repeated laboratory monitoring may cause financial and emotional burden for patients, the authors recommend reducing the tests to baseline, at 2 to 3 months, and upon completion of the isotretinoin treatment course.
– InYoung Kim, MD, PhD
Journal of the American Academy of Dermatology
Re-Evaluating the Need for Routine Laboratory Monitoring in Isotretinoin Patients: A Retrospective Analysis
Sent from my iPhone
Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica
Please excuse the shortness of this message, as it has been sent from
a mobile device.
Sent from my iPhone
Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica
Please excuse the shortness of this message, as it has been sent from
a mobile device.
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home